It is a third generation vaccine (recombinant DNA), i.e. made up of fragments of genetic information that encode immunogens. This is achieved by using a plasmid expression vector in mammal cells free of resistance to antibiotics, called pPAL, which has been patented by the research group. This vector was previously used for the construction of the pPAL-LACK vaccine optimized in GMP conditions. At the same time, it is based on positive results (phase IV) of protection obtained against canine leishmaniasis by vaccination of DNA molecules of protective antigens.
Principal Investigator: Vicente Larraga (CIB)